UCART20x22

Celldex Therapeutics reports significant progress in Phase 3 trials of barzolvolimab for chronic spontaneous urticaria (CSU), with active enrollment ongoing across 40 countries and 500 sites.

Cellectis' cash reserves surged to $264 million, fueled by a strategic investment and collaboration revenue from AstraZeneca, extending the company's financial runway to 2027.

Allogeneic "off-the-shelf" CAR-T cell therapies are emerging as alternatives to autologous CAR-T treatments, offering faster availability, reduced manufacturing complexity, and potentially lower costs for patients with B-cell malignancies.